Loading...
•
Mar 31
Geron Q1 2025 Earnings Report
Geron reported first quarter 2025 financial results and recent business highlights.
Key Takeaways
Geron Corporation reported $39.4 million in RYTELO net product revenue for Q1 2025, with total net revenue of $39.6 million. The company achieved approximately 85% enrollment in the Phase 3 IMpactMF clinical trial and received marketing authorization for RYTELO in the European Union.
Reported $39.4 million in RYTELO net product revenue in Q1 2025, with demand relatively flat.
Received marketing authorization for RYTELO from the European Commission (EC) and plans for commercial launch in select EU countries in 2026.
Reached approximately 85% enrollment in the Phase 3 IMpactMF clinical trial, with interim analysis expected in 2H 2026.
Ended Q1 2025 with approximately $457.5 million in cash, cash equivalents, restricted cash, and marketable securities.
Geron
Geron
Geron Revenue by Segment
Revenue by Segment
Product Revenue, Net Revenue
CapyFin.comRoyalties Revenue
CapyFin.com Forward Guidance
For fiscal year 2025, Geron maintains its total operating expense expectations in the range of approximately $270 million to $285 million. The company believes existing financial resources, combined with anticipated U.S. RYTELO sales, will be sufficient to fund projected operating requirements for the foreseeable future.
Positive Outlook
- Confidence in the long-term potential of RYTELO as an important therapeutic for lower-risk MDS patients.
- Strong therapeutic profile of RYTELO supported by positive clinician feedback.
- Focused investments to strengthen U.S. commercial trajectory and drive long-term demand for RYTELO.
- Expansion of medical affairs efforts to increase awareness and education.
- Progressing well with Phase 3 IMpactMF trial, representing a tremendous expansion opportunity.
Challenges Ahead
- Potential for inventory drawdown among RYTELO distributors to impact future revenue.
- Risks related to achieving market acceptance across all eligible patient segments for RYTELO.
- Uncertainty regarding approval timelines for imetelstat in other indications by FDA and European Commission.
- Potential for delays or adverse impacts from clinical, safety, efficacy, manufacturing, and regulatory challenges.
- Future safety or efficacy results of RYTELO treatment could cause its benefit-risk profile to become unacceptable.
Revenue & Expenses
Visualization of income flow from segment revenue to net income